References
- Fraile R J, Baker L H, Buroker T R. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res 1980; 40: 2223–2228
- Brower M, Carney D, Dainer P, Minna J. In vitro phase U trials of standard and escalated dose chemotherapy using cell lines of human non-small cell lung cancer (abstr). Proc Am Soc Clin Oncol 1983; 2: 34
- Benz C, Tillis T, Tattelman E, Cadman E. Optimal scheduling of methotrexate and 5-fluorouracil in human breast cancer. Cancer Res 1982; 42: 2081–2086
- Benz C, DeGregoria M, Saks S. Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity and response. Cancer Res 1985; 45: 3354–3358
- Clarkson B, O'Conner A, Winston L. The physiologic disposition of 5-FU and 5-fluoro-2′-deoxyuridine in man. Clin Pharmacol Ther 1964; 5: 581–610
- Shah A, MacDonald W, Goldie J. 5-FU infusion in advanced colorectal cancer: A comparison of three dose schedules. Cancer Treat Rep 1985; 69: 739–742
- Spiers A S, Kasimis B S, Janis M G. High-dose intravenous infusions of 5-fluorouracil for refractory solid tumors–the high-FU regimen. Clin Oncol 1980; 6(1)63–69
- Citron M, Nathan K, Kalra J. Phase HI inpatient and outpatient study of 24-hr. continuous infusion 5-fluorouracil (5-FU) for advanced cancers (abstr). Proc Am Soc Clin Oncol 1986; 5: 52
- Seifert P, Baker L, Reed M L, Vaitkevicius V K. Comparison of continually infused 5-ftuorouraciI with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123–128
- Chabner B. Pharmacologic Principles of Cancer Treatment. W.B. Saunders Co., Philadelphia 1982; 195
- Stein T A, Burns G P, Bailey B, Wise L. A method for the measurement of 5-fluorouracil and its metabolites in tissue. J Chromatogr 1990; 507: 259–263
- Ardalan B, Srkthar K S, Hussein A. Double biochemical modulation of 5-fluorouracil (5-FU) with phosphonacetyl-L aspartic acid (PALA) and leucovorin (LV): A phase I study (abstr). Proc Am Soc Clin Oncol 1990; 9: 104
- Schilsky R L, Perry M C, Citron M L. High dose 5-fluorouracil (5-FU) therapy for advanced gastrointestinal (GI) malignancy (abstr). Proc Am Soc Clin Oncol 1988; 7: 102